Pharmaceutical Executive

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts and the main factors that are contributing to the closures of both large and independent pharmacies, what alternative solutions can help ensure continued access to medications for all Americans (particularly those in underserved communities), some potential long term consequences if these pharmacy closures continue, and so much more

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses: Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs What needs to be done for GLP-1s to be covered Steps companies developing weight-loss medications should take to ensure responsible and ethical practice Advice for investors and financiers who are considering entering the weight-loss medication market

Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more. Link to Honeycomb Health video: https://www.pharmexec.com/view/going-beyond-visuals-to-connect-with-diverse-audiences

Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more. 

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.  Featured in this episode are: Emma Banks, CEO, ramarketing Jill Jaroch, Senior Director, Women’s Health & Urology Marketing, Astellas Marie Teil, Global Head, UCB’s Women of Childbearing Age Program Julia Lakeland, Chief Product Office, uMotif If you enjoyed this episode of our podcast, we encourage you to seek out the longer version of each of these videos—Linked on our website! 

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z, and how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract the ever elusive generation. 

Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more. 

Sameer Lal, Sr. Vice President at Indegene, shares his extensive knowledge in pharmacovigilance and AI from his 27 years in the industry. He talks about a new study illustrating customer perspectives on pharmacovigilance and the challenges in adopting AI technologies, revealing only 5% of organizations have done so. Lal emphasizes AI's potential to enhance data analysis and customer engagement while encouraging upskilling in the workforce. He also compares generative AI's impact on pharma to major tech revolutions, marking an exciting future for innovation.

Dr. Julien Boisdron, Global Head of OneMedical / Chief Medical Officer Roche Diabetes Care, discusses the current standard for diabetes care, the importance of patient advocacy and mental health, what the future of this space holds, and much more.